Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Miami Lakes, Florida Clinical Trials

A listing of Miami Lakes, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (389) clinical trials

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the correction of anemia and maintenance of Hb in subjects with NDD-CKD

Phase

0.0 miles

Learn More »

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with NDD-CKD

Phase

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate the safety and efficacy over 12 weeks of FMX101 topical foam containing 4% minocycline compared to vehicle in the treatment of subjects with moderate-to-severe facial acne vulgaris. Qualified subjects will be randomized to receive 1 of the following ...

Phase

0.0 miles

Learn More »

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

The primary objective is to assess the durability of effect of bimagrumab (BYM338) as measured by the short physical performance battery (SPPB) total score at week 49.

Phase

0.87 miles

Learn More »

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

This is a dose-finding, open-label, single agent study of RX-3117. Once the maximum tolerated dose is identified additional subjects will be treated in a dose expansion followed by a 2-stage Phase 2 study. Subjects will be treated for up to 8 cycles of therapy. A cycle will be 4 weeks. ...

Phase

0.87 miles

Learn More »

Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain

Subjects, once stabilized to Embeda, need only complete a minimum of 2 of the 6 week study duration to satisfy the PK endpoint. A safety follow-up visit is required at 1 week post-last dose.

Phase

0.87 miles

Learn More »

Dose Range Finding Study of Bimagrumab in Sarcopenia

The purpose of this study is to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study will generate data on the safety, tolerability, and pharmacokinetics of bimagrumab in older ...

Phase

0.87 miles

Learn More »

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

This is a multi-site, placebo-controlled, double-blind, randomized withdrawal, time to intervention study with a duration of up to 36 weeks, consisting of 5 periods: Screening Period: up to 4 weeks duration; Open-Label Titration Period (Titration Period): up to 4 weeks duration; Open-Label Treatment Period (Open-Label Period): 12 weeks duration; Double-Blind ...

Phase

0.87 miles

Learn More »

Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS

Multicenter, multiple dose study to examine the effect of H.P. Acthar Gel (repository corticotropin injection) in adult subjects with idiopathic focal segmental glomerulosclerosis (FSGS) who have failed to achieve remission with, or who are intolerant of, 1 or more previous immunosuppressive therapies.

Phase

0.87 miles

Learn More »

Pharmacokinetics and Pharmacodynamics of GS-9674 in Adults With Normal and Impaired Hepatic Function

The primary objective of this study is to evaluate the single-dose pharmacokinetics of GS-9674 in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.

Phase

0.87 miles

Learn More »